pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,990 catalysts · 5,990 phase readout · 2,344 8k filing · 413 earnings · 3 pdufa · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 95 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: phase readout×type: recall×type: filing×clear all
type
  • phase readout5,990
  • 8k filing2,344
  • earnings413
  • pdufa3
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›ACTIVE_NOT_RECRUITINGphase readoutNCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Phase: PHASE2. Conditions: Lymphoma, Large B-Cell, Diffuse

full page →ctgov ↗
›RECRUITINGphase readoutNCT06040762: A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial

Sponsor: University of Washington. Phase: NA. Conditions: Bladder Cancer, Urothelial Carcinoma, Upper Tract Urothelial Carcinoma, Renal Pelvis and Ureter Urothelial Carcinoma

full page →ctgov ↗
›WITHDRAWNphase readoutNCT06005662: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Sponsor: Johns Hopkins University. Phase: PHASE2. Conditions: Opioid Use Disorder

full page →ctgov ↗
›COMPLETEDphase readoutNCT02104362: Single Fraction Early Prostate Irradiation (SiFEPI)

Sponsor: Centre Antoine Lacassagne. Phase: NA. Conditions: Prostate Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT07483788: Short Term Comparative Assessment of MTA and Biodentine in Complete Pulpotomy for Symptomatic Irreversible Pulpitis

Sponsor: Dow University of Health Sciences. Phase: NA. Conditions: Symptomatic Irreversible Pulpitis (SIP)

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03251027: Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. Phase: NA. Conditions: Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma

full page →ctgov ↗
›RECRUITINGphase readoutNCT07344961: Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)

Sponsor: Northwell Health. Phase: . Conditions: Paroxysmal Atrial Fibrillation

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05970042: Investigating the Effects of the "GameDay Ready" Behavioral Weight Management Program for Black Men Living in the Rural South

Sponsor: University of South Carolina. Phase: NA. Conditions: Obesity

full page →ctgov ↗
›TERMINATEDphase readoutNCT05416086: iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study

Sponsor: Adagio Medical. Phase: NA. Conditions: Atrial Fibrillation, Atrial Flutter, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation

full page →ctgov ↗
›COMPLETEDphase readoutNCT06571370: Wave Crossover ECP Study for Simplified Therapy

Sponsor: Pression. Phase: NA. Conditions: Chronic Stable Angina, Refractory Angina

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03451370: First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer

Sponsor: Istituto Oncologico Veneto IRCCS. Phase: . Conditions: Elderly Metastatic Colorectal Cancer Patients

full page →ctgov ↗
›RECRUITINGphase readoutNCT06778070: National Program to Overcome Pelvic Pain studY (POPPY)

Sponsor: University of California, San Francisco. Phase: NA. Conditions: Chronic Pelvic Pain Syndrome (CPPS), Chronic Pelvic Pain Syndrome, Chronic Pelvic Pain

full page →ctgov ↗
›RECRUITINGphase readoutNCT05431270: Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Sponsor: Phanes Therapeutics. Phase: PHASE1. Conditions: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT07093073: Clinical Study of U01(ssCART-19) in Patients With B-Cell Lymphoma

Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd. Phase: PHASE1. Conditions: B Cell Lymphoma

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT07294573: Maternal Health Assessment in Pediatric Care

Sponsor: John James Parker. Phase: NA. Conditions: Postpartum Care, Primary Care, Mental Health, Family Planning, Care Coordination

full page →ctgov ↗
›COMPLETEDphase readoutNCT07567573: Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery

Sponsor: European Society of Gynaecological Oncology. Phase: . Conditions: D010051, Ovarian Cancer, Advanced-stage Ovarian Cancer, FIGO Stages III and IV, Quality Indicators

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07545369: ULTRA-EVOLUT RCT: A Comparison of Latest-Generation TAVR Valves

Sponsor: Assiut University. Phase: NA. Conditions: Severe Aortic Valve Stenosis

full page →ctgov ↗
›COMPLETEDphase readoutNCT07531069: Efficacy and Safety of Interferon-Gamma Monoclonal Antibody Combined With Dexamethasone in the Treatment of Refractory Adult Secondary Hemophagocytic Lymphohistiocytosis

Sponsor: Fudan University. Phase: . Conditions: Adult Refractory Secondary Hemophagocytic Lymphohistiocytosis, Secondary Hemophagocytic Lymphohistiocytosis, HLH

full page →ctgov ↗
›COMPLETEDphase readoutNCT02975869: A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia

Sponsor: Massachusetts General Hospital. Phase: NA. Conditions: Acute Myeloid Leukemia

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT01983241: Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Sponsor: Grifols Therapeutics LLC. Phase: PHASE3. Conditions: Pulmonary Emphysema in Alpha-1 PI Deficiency

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07395154: Comparison of Integrated Neuromuscular Inhibition Technique (INIT) and Active Release Technique (ART) in Patients With Upper Trapezius Trigger Points

Sponsor: Lahore University of Biological and Applied Sciences. Phase: NA. Conditions: Myofascial Pain Syndrome

full page →ctgov ↗
›COMPLETEDphase readoutNCT04142905: Is Asthma in Subjects With Obstructive Sleep Apnoea (OSA) Due to Dysanapsis

Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust. Phase: . Conditions: Asthma, Obstructive Sleep Apnoea (OSA), Dysanapis

full page →ctgov ↗
›COMPLETEDphase readoutNCT03789266: Drains Ablation Post Total Hip Arthroplasty : Search for the Least Painful Technique

Sponsor: University Hospital, Rouen. Phase: NA. Conditions: Total Hip Arthroplasty, Drain Insertion Site

full page →ctgov ↗
›RECRUITINGphase readoutNCT04844866: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Sponsor: Miltenyi Biomedicine GmbH. Phase: PHASE2. Conditions: Diffuse Large B-cell Lymphoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT07703722: Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder

Sponsor: Khyber Medical University Peshawar. Phase: PHASE3. Conditions: Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)

full page →ctgov ↗
›RECRUITINGphase readoutNCT07329231: Quinoa Improves Glycolipid Metabolism and Glucose Fluctuation Based on β-Cell Function in Early-stage Type 2 Diabetes

Sponsor: Qilu Hospital of Shandong University. Phase: NA. Conditions: Type 2 Diabetes Mellitus (T2DM)

full page →ctgov ↗
›RECRUITINGphase readoutNCT05332002: sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

Sponsor: Rutgers, The State University of New Jersey. Phase: PHASE2. Conditions: Gastro-Intestinal Cancer

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT01728402: Pathogenesis of Hematologic Malignancies

Sponsor: OHSU Knight Cancer Institute. Phase: . Conditions: Acute Leukemia, Lymphoproliferative Disorders, Myeloproliferative Disorders, Myelodysplastic Syndromes

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT07704931: Pilot Study to Evaluate Changes in Intra-Epidermal Nerve Fiber Density (IENFD) in Patients With Small-Fiber Neuropathy

Sponsor: TriCity Research Center. Phase: NA. Conditions: Small Fiber Neuropathy

full page →ctgov ↗
›RECRUITINGphase readoutNCT07240831: Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

Sponsor: Biobeat Technologies Ltd.. Phase: NA. Conditions: Blood Pressure, Heart Disease, Hypertension (HTN), Blood Pressure Monitoring

full page →ctgov ↗
›RECRUITINGphase readoutNCT06012695: NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Sponsor: Novelwise Pharmaceutical Corporation. Phase: PHASE1. Conditions: Malignant Neoplasm, Malignant Neoplasm of Brain

full page →ctgov ↗
›RECRUITINGphase readoutNCT07187245: Feasibility of the Reality PAWS Program for Children in Isolation

Sponsor: Children's Hospital Colorado. Phase: NA. Conditions: Inpatient Pediatric Care, Isolation, Feasibility Studies

full page →ctgov ↗
›RECRUITINGphase readoutNCT06678672: Contingency Management for Veteran Smokers Undergoing Major Elective Surgery

Sponsor: University of California, San Francisco. Phase: NA. Conditions: Tobacco Use Disorder, Substance Use Disorder (SUD)

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07620639: Consciousness Studies and Cardiovascular Health

Sponsor: University of Miami. Phase: NA. Conditions: Blood Pressure, Relaxation, Virtual Reality

full page →ctgov ↗
›SUSPENDEDphase readoutNCT04306939: Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

Sponsor: University of Pittsburgh. Phase: . Conditions: Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic

full page →ctgov ↗
›RECRUITINGphase readoutNCT02339012: Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)

Sponsor: National Institute on Aging (NIA). Phase: . Conditions: Healthy Volunteers, Non-Healthy/Non-Frail, Frail

full page →ctgov ↗
›SUSPENDEDphase readoutNCT06379581: Skin Cancer Diagnostics Using Photoacoustic Imaging

Sponsor: Region Skane. Phase: . Conditions: Skin Cancer

full page →ctgov ↗
›COMPLETEDphase readoutNCT07227519: Effects of UPF Warning Labels on Social Media Among Teens and Young Adults

Sponsor: University of Tennessee. Phase: NA. Conditions: Nutrition, Healthy Diet, Food Preferences

full page →ctgov ↗
›RECRUITINGphase readoutNCT07269119: Piloting a Deaf Accessible Pre-Treatment for AUD

Sponsor: University of Massachusetts, Worcester. Phase: NA. Conditions: Alcohol Use Disorder

full page →ctgov ↗
›TERMINATEDphase readoutNCT02151019: Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer

Sponsor: Cancer Trials Ireland. Phase: PHASE1. Conditions: Locally Advanced Rectal Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT07073430: Application Evaluation Research on the Artificial Intelligence-assisted Support System for the Diagnosis of Colorectal Tubular Adenoma Lesions

Sponsor: Renmin Hospital of Wuhan University. Phase: . Conditions: Colorectal Adenoma, Artificial Intelligence (AI)

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT07143630: Abdominal Electrical Stimulation for Balance and Muscle Thickness in Stroke Patients

Sponsor: Başakşehir Çam & Sakura City Hospital. Phase: NA. Conditions: Stroke

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT06133530: Human Milk Oligosaccharides (HMOs) and Gut Microbiota, Immune System in Antarctica

Sponsor: IU University of Applied Sciences. Phase: NA. Conditions: Healthy Adults, High Altitude, Isolation, Social

full page →ctgov ↗
›RECRUITINGphase readoutNCT05851430: Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry

Sponsor: Galvanize Therapeutics, Inc.. Phase: . Conditions: Soft Tissue Lesion

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07564830: Association Between Sarcopenia, Fatigue and Orthostatic Intolerance in Geriatric Patients: A Case Control Study

Sponsor: Ain Shams University. Phase: . Conditions: Sarcopenia, Fatigue, Orthostatic Intolerance

full page →ctgov ↗
›COMPLETEDphase readoutNCT07736430: Evaluation of Pin Buckle Bone Plates for Management of Anterior Mandibular Fractures

Sponsor: Suez Canal University. Phase: NA. Conditions: Mandibular Fractures, Symphysis Fractures, Parasymphysis Fractures

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07583030: A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Phase: EARLY_PHASE1. Conditions: Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD), Progressive Multiple Sclerosis (PMS), Relapsed/Refractory Myasthenia Gravis(r/r MS)

full page →ctgov ↗
›RECRUITINGphase readoutNCT07083661: Mindfulness-based Intervention and Young Children's Screen Time

Sponsor: Hong Kong Metropolitan University. Phase: NA. Conditions: Screen Time Exposure

full page →ctgov ↗
›COMPLETEDphase readoutNCT05918042: A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation

Sponsor: AstraZeneca. Phase: . Conditions: Ovarian Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT06096142: The Solaris DE Endoprosthesis for the Treatment of AV Access Stenosis or Occlusion

Sponsor: Scitech Produtos Medicos SA. Phase: NA. Conditions: Venous Stenosis, Venous Occlusion, Chronic Renal Failure

full page →ctgov ↗
← prev
page 119 of 120
next →